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a b s t r a c t
Operations research (OR) is well established in India and is also a prominent feature of the global and
local agendas for tuberculosis (TB) control. India accounts for a quarter of the global burden of TB and
of new cases. Multidrug-resistant TB is a significant problem in Mumbai, India’s most populous city,
and there have been recent reports of totally resistant TB. Much thought has been given to the role
of OR in addressing programmatic challenges, by both international partnerships and India’s Revised
National TB Control Programme.We attempt to summarize themajor challenges to TB control inMumbai,
with an emphasis on drug resistance. Specific challenges include diagnosis of TB and defining cure,
detecting drug resistant TB, multiple sources of health care in the private, public and informal sectors, co-
infection with human immunodeficiency virus (HIV) and a concurrent epidemic of non-communicable
diseases, suboptimal prescribing practices, and infection control. We propose a local agenda for OR:
modeling the effects of newer technologies, active case detection, and changes in timing of activities,
and mapping hotspots and contact networks; modeling the effects of drug control, changing the balance
of ambulatory and inpatient care, and adverse drug reactions; modeling the effects of integration of TB
and HIV diagnosis and management, and preventive drug therapy; and modeling the effects of initiatives
to improve infection control.
© 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Operations research, India, and tuberculosis
India has operations research (OR) history. Established in 1957
and affiliated with the International Federation of Operational
Research Societies (IFORS), the Operational Research Society of
India was the first in the South, and hosted the first international
conference on OR for Development, in Ahmedabad in 1992
(ORSI: www.orsi.in). Nevertheless, OR on public health has been
limited, and in this India is no exception [1,2]. In a recent
discussion, Royston suggests that OR has a rather broader
interpretation in global health than in management science [3].
Health initiatives have tended to use group methods of qualitative
character (brainstorming, behavioral simulation, scenario analysis,
system mapping), rather than quantitative exercises such as
mathematical modeling and system dynamics. We think this is
true, but understandable. Proponents of OR for global health –
and for TB control in particular – see it as research ‘‘intended
to provide managers, administrators, and policy makers with
the information that they need to improve service delivery
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Open access under CC BY license.activities and plan future ones’’ [4]; or, ‘‘research into strategies,
interventions, tools or knowledge that can enhance the quality,
coverage, effectiveness or performance of the health system or
programmes in which the research is being conducted’’ [5,6]. This
sort of language is less intimidating than ‘‘an interdisciplinary
branch of applied mathematics or formal science that uses
advanced analytic methods to make better decisions or research
that provides optimal solutions to complex decision-making’’
(http://www.scienceofbetter.org/what/index.htm).
It turns out that OR for health in low-income countries has been
championed by people involved in tuberculosis (TB) control, from
making the case for OR [5,7–9] to more tightly specified agendas
[10,11]. The sort of OR that might be described as implementation
science is crucial to the success of TB programmes [12,13],
and guided the development of current approaches based on
Directly Observed Therapy Short-course (DOTS) [11]. Substantial
efforts have been made to support OR for TB control through
funding, training and guidelines, but it is not always clear that
it has delivered [11]. Commentaries call for greater coordination
— for activity to be more programme-driven than researcher-
driven — [9] and for a clear sequence of steps from research to
implementation [8].
The current WHO Stop TB Strategy has six concerns: (i) high-
quality management of TB through DOTS, (ii) co-infection with TB
and human immunodeficiency virus (TB-HIV), multidrug-resistant
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(iii) health systems, (iv) multiple providers of health care, and
(v) partnerships with people with TB [14]. The sixth concern is
the need for research, and the Global Plan to Stop TB 2011–2015
is unusual in emphasizing OR (http://www.stoptb.org) [15].
Tuberculosis in India
Nowhere is the OR agenda more pressing than in India, which
accounts for 25% of the global burden of TB and 29% of global TB
mortality [16]. TB causes an estimated 320 000 annual deaths in
India: 17.6% of communicable disease deaths and 3.5% of all-cause
mortality [17]. While the incidence has fallen from 216 to 185 per
100 000 over the last decade, notifications reached 1.5 million in
2010. 1.2million of these were new cases. India contributed 23% of
new diagnoses of TB globally, but 43% of individuals who required
retreatment. The primary notional provider of care is the Revised
National TB Control Programme (RNTCP): Fig. 1 is an overview of
major activities.
Mumbai
If onewanted to design an environment conducive to the spread
of TB, failure of treatment, and emergence of resistance, Mumbai
would fit the remit. A land-starved megacity in which a resident
population of 12.5 million are compressed into 437 km2 [18],
Mumbai combines extreme population density with inadequate
water, sanitation, and solid waste management, indoor and
outdoor air pollution, an unbridled multiplicity of healthcare
providers, inequalities startling in their visibility and proximity,
and an epidemic of predisposing malnutrition and illness. The
city has a mean population density of 49 000 per km2 [19], over
half of whom live in the informal settlements, zopadpattis, bastis
and chawls loosely described as slums [18]. TB is a disease of
poverty and marginality [20], and the UN-HABITAT definition of a
slum could double as a pro-tuberculotic checklist: overcrowding,inadequate safe water and sanitation, poor housing fabric, and
insecurity of tenure [21]. Coupled with this are epidemics of non-
communicable disease: 34% of women have low body mass index,
and 44% are anaemic, and 46% of children in the poorest quartile
are underweight [22]. Tobacco and alcohol use are common, and
diabetes — which affects an estimated 40 million Indians [23] —
has a prevalence of 1900 per 100 000 in slum-dwelling men and
1170 in women.
Mumbai houses 12% of the population of Maharashtra state,
but accounts for 22% of notified cases of TB and — significantly
in terms of potential drug resistance — 50% of people undergoing
retreatment after relapse (SHRC, unpublished data). TB treatment
is estimated at 600 per 100 000 in slum areas and 458 in non-slum
areas [19,22]. The RNTCP registered∼30 000 people for treatment
in 2010, of whom ∼15 000 were smear-positive and ∼2000 (9%)
were children. Given that 50%–70% of people seeking treatment do
so in the private sector [24], the incidence of TB inMumbai is likely
to be at least 60 000 cases annually; half of them documented in
terms of type, treatment, and outcome.
The emergence of drug-resistant TB in Mumbai is a prospect so
alarming that the paucity of available evidence may be a case of
‘out of sight, out of mind’. What reports there are have consistently
shown higher levels of MDR-TB (resistant to the 2 first-line drugs
rifampicin and isoniazid) than in other parts of India, at 24%–30%
of new cases [25,26] and 11%–67% of treated cases [25–27] (the
corresponding figures from other parts of the country are 1%–13%
and 12%–40%, respectively [28–35]). Extensively drug-resistant
(XDR) TB (MDR-TB that is also resistant to both a fluoroquinolone
and a second-line injectable agent) was detected in Mumbai in
2005 [36], but the most nightmarish of scenarios has been evoked
by a recent report of totally drug resistant (TDR) TB [37].
In the fallout from the TDR-TB findings, which came from
Hinduja Hospital and were widely reported [38], the local
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are the establishment of MDR-TB as a notifiable disease and
the introduction of Xpert MTB/RIF R⃝ (an automated nucleic acid
amplification test) to facilitate rapid, quality drug susceptibility
testing (DST). DOTS Plus regimenswill be provided to clients failing
first-line treatment by the public sector. More general proposals
include increased human resources (the designation of each of
the 24 municipal wards as a ‘TB district’, such that each would
have its own TB control officer), training for healthcare cadres,
improved infection control at TB hospitals (though not currently
at peripheral facilities), and house-to-house visits and surveys in
vulnerable areas. A combination of public–private mix models and
efforts to control prescribing practices is proposed, with the idea
that pharmacists’ associations might be involved in controlling
over-the-counter sale of anti-TB medication.
2. Existing recommendations for operations research
Lienhardt and Cobelens categorize OR needs at three levels:
improving programme performance and outcomes, assessing
the feasibility, effectiveness or impact of new strategies or
interventions on TB control, and collecting data to guide policy
on specific interventions [11]. These map roughly onto local-or-
national, national-or-regional, and regional-or-international tiers.
There are serious concerns about TB control in Mumbai and we
locate the OR needs on the local-national tier, clustered around
programmatic issues: case-finding and diagnosis, ascription of
drug sensitivity, delivery of appropriate treatment, follow-up,
definition of cure or failure, and management of default (dropping
out of the treatment programme), relapse, and drug resistance.
These issues are by nomeans unique, but they are context-specific.
The Stop TB Partnership calls for OR under four general themes:
(i) improving access, screening and diagnosis, (ii) sustainable
collaboration with all care-providers, (iii) prevention of TB in
people living with HIV, and joint treatment of HIV and TB, and
(iv) access to and delivery of treatment. A fifth category applies
specifically to OR [10]. India’s RNTCP has also developed detailed
OR guidelines and an action plan, overseen by a central research
cell, a national standing committee, and state-level OR committees.
The agenda includes topics of primary and secondary importance,
breaks them down in terms of whether they would best be
addressed by research institutes, medical colleges, RNTCP units,
or postgraduate students, and calls for proposals every six months
[39]. Table 1 compares priority areas from both sets of guidelines.
3. Specific challenges for tuberculosis control in Mumbai
3.1. Improving access, screening and diagnosis of tuberculosis
Diagnosing tuberculosis
New cases entering the RNTCP are diagnosed by sputum
microscopy, which is also used for follow-up. In principle, we
do not know whether or not they represent MDR-TB (although,
once diagnosed, treatment under the DOTS Plus regimen is
monitored by sputum culture). It may also not be clear whether
they are really ‘new’, or whether they have received treatment
before. Misclassification has been reported in 13% of cases in
Mumbai [40]. The reasons for this are both microbiological and
systemic. Insufficient efforts to screen clients have been attributed
to workload and negligence, even when clear guidelines were
available. Clientsmay not have kept records of previous treatment,
and may be reluctant to mention it for fear of either stigma
or refusal to provide further treatment [40]. The target-oriented
approach of the RNTCP may also predispose health workers to
classify clients as new [41].Defining cure
Microscopy performed on unconcentrated sputum samples has
limited sensitivity, the concern being that it can lead to over-
ascription of cure and a higher likelihood of relapse. Relapses
constitute 38% of retreatment cases in India — six times asmany as
treatment failures. A study in Delhi found relapse in 9% of people
who had been classified as cured [42], and over half of retreatment
episodes occurred after RNTCP treatment [43]. The relatively good
outcomes seen in three-quarters of these episodes suggest that the
initial treatment might not have been optimal [42,44]. Levels of
MDR-TB in treatment after relapse are 11%–27%, lower than after
default, and lower in turn than after treatment failure [29,35,45].
Detecting drug resistant tuberculosis
India has 15 laboratories accredited for DST (RNTCP Perfor-
mance Report, 2nd Quarter, 2011), much below the recommended
population provision of one per 5 million. Most laboratories use
solid culture, the turnaround time for which is 8–12 weeks. Three
laboratories use line probe assays (LPA: nucleic acid amplifica-
tion and tagging for resistance) that can provide results within a
day. Of Mumbai’s 2 accredited laboratories, one uses liquid culture
(turnaround 4 weeks) and the other — recently accredited — LPA.
Theprocess of coordination between these facilities in handling the
city’s MDR-TB load is unclear.
3.2. Sustainable collaboration with all care-providers for tuberculosis
control
Choice of provider
India’s private sector provides 70%–80% of outpatient consul-
tations, almost 70% of hospitals and 40% of hospital beds [46–48].
With 50 large private hospitals, 2000 nursing homes, and 8000–10
000 individual private practitioners [49], Mumbai offers a wide
range of medical services to its inhabitants [50,51], many of them
an amalgamof allopathic and traditionalmedicine [52]. For TB con-
trol, this represents what Babu and Laxminarayan describe as a
poverty of plenty [53].
Studies on care-seeking suggest that about half of people with
chest symptoms make a first approach to a government facility,
but the preference for private sector health care has been well
described. The pull and push factors are familiar: proximity and a
perception of better quality of care, underscored by dissatisfaction
with public sector service timings, crowds and waiting times, staff
availability, quality and attitude [54–56].Women seemmore likely
than men to see private practitioners for an initial consultation for
a cough [57], and the stigma of TB may make themmore reluctant
to undergo sputum examination [58]. Parents may conceal the fact
that their daughter has TB because of concerns about her marriage
prospects [59].
Although choice of health care may be influenced by awareness
of available services [60], financial constraints are themajor reason
for opting for treatment fromgovernment facilities [54,55,61]. Cost
may not be a threshold factor, but it is a limiting factor [22].
Awareness of the availability of free medicines at government
facilities does not necessarily encourage uptake [62], and clients
only move from private to public sector when the duration of their
illness and the costs associated with long-term private care begin
to bite [54]. ‘Treatment shopping’ has often been cited as a reason
for delay in approaching the RNTCP [54]; understandable, perhaps,
in a market in which people who stick with a single provider end
up spending more [62]. One study estimated the average number
of providers seen before approaching the RNTCP at 2, although
this correlated more with the inability of providers to correctly
diagnose TB than with client-driven shopping [54].
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Recommendations for operations research, adapted from Stop TB Alliance [10] and RNTCP guidelines [39].
Stop TB OR recommendations RNTCP immediate priority areas for OR
Improving access, screening and diagnosis of TB Interventions to improve case detection and diagnosis
How to improve access to TB diagnosis? Care seeking behavior and reasons for diagnostic delay in vulnerable
populations, including urban slum dwellers.
How to improve screening of TB suspects and high-risk groups? Pilot test of ‘‘2+ 2’’ (2 weeks cough and 2 sputum specimens) for TB
suspect identification and diagnosis in high and low workload settings.
How to use the introduction of new tools to improve service delivery practices? Yield of sputum-smear examination for extrapulmonary TB at diagnosis,
and predictive value of follow-up sputum-smear examination in
extrapulmonary and smear negative TB.
How to improve active TB case-finding? Prevalence of cough>2 weeks among outpatients, and smear microscopy
outcomes among them.
How to build accessible, effective and efficient diagnostic services with new diagnostic
tools?
How to evaluate the impact of new tests or new approaches?
Prevention of TB in people living with HIV, and joint treatment of HIV and TB Interventions to address TB/HIV
What are the barriers to TB diagnosis, and how to overcome them? Evaluation of screening methods for TB case-finding in antiretroviral
treatment, HIV care and support centers.
What are the barriers to initiation of isoniazid preventive therapy? Reasons for loss of TB suspects referred from integrated counseling and
testing centers to microscopy centers.
What are the barriers to optimal combined TB/HIV diagnosis and treatment, and what
are the optimal models for joint TB and HIV care activities?
Reasons for non-initiation of ART for clients with TB and HIV.
Incidence and mortality associated with TB among clients awaiting ART
and on ART.
Access to and delivery of treatment for drug-susceptible and M/XDR-TB Interventions to address drug-resistant TB
What are the drivers of drug-resistant TB at individual and programmatic levels? Prevalence of MDR-TB in Category I failures, Category II entry, and Category
II clients smear positive at 3 months, and association of MDR-TB with
source of and past history of anti-TB treatment.
What are the potential strategies for integration/scale up of drug-resistant TB
management within TB control programmes?
Evaluation of innovative methods of community-based DOT provision for
the delivery of RNTCP Category IV treatment.
Rapid case-control study for risk factors for fluoroquinolone resistance and
XDR-TB among clients with MDR-TB.
Use of second-line anti-TB drugs and MDR-TB diagnostic and treatment
practices among providers in urban areas (surveys).
Sustainable collaboration with all care-providers for TB control Interventions to engage all health care providers
How to improve and scale up existing approaches to engaging all care-providers? Evaluation of the quality of TB diagnosis and care among private sector
physicians.
How to measure the contribution of different provider groups to TB care and control? Marketing to private health providers: what messages change referral,
diagnostic, and treatment behavior for TB?
How to encourage involvement of as yet unengaged providers? Evaluation of comparative results and effort required by the different
RNTCP schemes to involve private practitioners.
How to encourage involvement of the non- public sector in MDR-TB management and
TB/HIV collaborative activities?
Knowledge, attitudes and practices of providers of alternative systems of
medicine.
How to develop and assess responses to changing involvement of diverse providers in
TB care and control?
Testing methods to involve providers of alternative systems of medicine in
the referral of TB suspects.
How to encourage introduction of regulatory approaches to collaborating
care-providers?
Access to and delivery of treatment for drug-susceptible and M/XDR-TB Improving community access to TB services
What are the reporting gaps and deficiencies in first-line management of TB cases? Qualitative (focus groups) and quantitative (pre-and post intervention)
evaluation of the effectiveness of communication methods and messages
to promote client demand.
How to address these deficiencies and improve management of drug-sensitive TB? Testing innovative interventions to increase public visibility of TB diagnosis
and treatment facilities.
How to reinforce PPM collaboration for treatment of sensitive- and resistant TB? Efficacy and cost of innovations to increase demand by people with
respiratory symptoms in primary care.
How to improve decentralized and fully integrated access to TB and antiretroviral
treatment?
Interventions to improve treatment outcomes
Prospective, community-based, long-term cohort study of RNTCP clients:
Risk factors for death, default, and treatment failure. Impact of migration
on treatment outcomes. Impact of diabetes and HIV infection on treatment
outcomes. Impact of non-MDR drug resistance on treatment outcomes.
Incidence and risk factors for relapse and reinfection. Risk factors for death
after treatment.
Evaluation of reasons for initial default and effectiveness of interventions
to prevent it.
Cluster randomized controlled trial of innovative and cost-effective
programme interventions to reduce default.
Impact on outcome and relapse of daily or partially intermittent treatment
(2 weeks daily) during the intensive phase of TB treatment, compared with
fully-intermittent regimen, in clients with and without HIV infection.
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The RNTCP has undertaken an extensive programme of collab-
oration with private and non-government practitioners. With the
institution of referral processes, clarification of roles, and amend-
ments to recording systems, the collaboration increased diagnoses
of new smear positive TB by 40% [49]. Public–private mix projects
have shown promising cure rates in other cities [63]. Clients in
Delhi seemed to be satisfied with the arrangements, although the
default rate was 14% [64]. There were also savings to the RNTCP
because of the contribution of private sector facilities and human
resources [65]. This contribution is, however, a potential limit to
sustainability. Private providers, many of them single-handed and
at the edge of profitability, often balk at the human resources and
support systems necessary for monitoring, tracing defaulters, and
record keeping [66].
3.3. Prevention of TB in people living with HIV, and joint treatment of
HIV and TB
Co-infection with HIV
For Indians infected with Human Immunodeficiency Virus
(HIV), the chance of developing active TB is 50%–60%, compared
with 10% in the general population [67,68]. The prevalence of HIV
is 0.34%, but the distribution is uneven [69], and this is reflected
in HIV seroprevalence in people with TB. The national prevalence
in notified TB infections is 5%–8% [70–72], with a variation of
between 0.5% and 13.5% depending on location [73–77]. This
poses operational challenges for the design and implementation
of collaborative TB and HIV interventions [76].
Currently, 49% of people in India known to have HIV infection
receive antiretroviral therapy (ART). The figure for Mumbai is
35% [72]. Death during TB treatment in HIV infected individuals
is strongly associated with the absence of ART, independent of
gender andprevious TB treatment,which implies that programmes
should promote high levels of ART uptake and monitor progress
closely [77]. Treatment of TB in the presence of HIV is complex in
terms of regimen duration, dosage and frequency of anti-TB drugs,
optimal timing of initiation of ART, and optimal drug combination
for people on second-line treatment [78]. In a study of clients
on ambulatory treatment for MDR-TB-HIV in a slum setting in
Mumbai, cure rates were 31% and treatment completion 17% at
2 years [79]. The relative success of community-based care was
attributed to a one-stop service for TB and HIV, early management
of adverse drug effects, psychosocial support, and administration
of drug combinations based on DST results.
Diabetes
Among the epidemics that India finds itself facing is rampant
diabetes mellitus. Case-control studies suggest odds ratios for
developing TB of 2.4–8.3 in the presence of diabetes [80–84].
Smear positive TB was seen in 6% of diabetic clients in a study in
eastern India [85], and diabetes was the most common risk factor
for pulmonary TB in south Indian studies [81,86]. Mathematical
models suggest that it accounts for 15% of pulmonary TB and 20%
of smear-positive (infectious) TB in India [87]. Annual cases of
TB in people with diabetes increased by 46% between 1998 and
2008 [88], and diabetes is associated with a 15% greater incidence
of smear-positive TB in urban than in rural areas [87]. Modeling
also suggests that the incidence of TB would have increased (by
28%) faster than population size (at 22%) because of the effects of
aging, urbanization, changing body mass index and rising diabetes
prevalence [87]. It is not certain whether people with diabetes are
more likely to develop MDR-TB [89–93], although the levels are
substantial in Indian clinics [94,95]. Diabetes may also exacerbate
the hepatotoxicity of anti-tuberculous drugs [96].3.4. Access to and delivery of treatment for drug-susceptible and
M/XDR-TB
Prescribing practices
That treatment practices in the private sector are largely
unregulated has been an issue for years [97]. Inappropriate TB
regimens have been documented in the majority of indigenous
medical practitioners [98], private practitioners in a slum area
[24], and also in chest physicians [99]. A study in Delhi suggested
that when health workers thought that patients were poor,
marginalized, or itinerant, they might not begin DOTS because of
the assumption that they would not adhere [100].
Spurious drugs
Use of substandard medications is analogous to inadequate
therapy and could lead to drug resistance and treatment failure,
despite 100% adherence [101]. An analysis of single and fixed-
dose combinations of isoniazid and rifampicin available in India
found 13% to be substandard, and themean content of 100 samples
of rifampicin purchased from pharmacies in Chennai was below
pharmaceutical standards [102,103].
The problem of default
Dropping out of a treatment programme — and increasing the
risk of development of MDR-TB — is the result of an interplay
of client and provider factors. Key predispositions include a
combination of relief from symptoms, the need to work, and
stigma. Side-effects of treatment were cited as a reason for default
by 10%–50% of defaulters [58,104,105], and default is commoner in
men and alcohol users [104–106]. Migration during the extended
period of treatment is clearly an issue, as are distance to services,
DOTS service opening times, the need to travel while unwell, and
costs of travel (three times a week in the case of DOTS) [104,106].
It is possible that DOTS provision by local generalists such as
anganwadi workers is less liable to default than provision by
specific DOTS centers, possibly because of proximity and ease
of access, and possibly because of a less overt labeling of the
problem as TB [58]. People who have defaulted previously, or who
have been treated previously outside the RNTCP system, are more
likely to default [104,105,107]. Provider-related issues include
poor communication and lack of attention and support fromhealth
workers, especially when patients experience side-effects [104].
The peak time for default is at the end of the intensive phase
and beginning of the continuation phase of treatment [105]. When
clients default, healthcare workers are responsible for tracing
them. These clients, however, may be labeled as ‘unlikely to
comply’ and likely to ‘spoil the results of a TB center’. They may be
treated insensitivelywhen they return for care, or asked to produce
a guarantor that they will complete the course [100,104].
Infection control and transfer of resistance
Infection control is a relatively neglected aspect of TB —
particularly MDR-TB — prevention. With its high caseloads,
Mumbai faces overwhelming numbers of clients in conditions in
which repeatedmutual exposure is common. Respiratory isolation
wards, adequate ventilation and sunlight, and availability of N95
respirators are limited in clinical settings, and the provision of
TB clinics within maternity care facilities, schools, and residences
introduces a worrying level of unnecessary exposure to vulnerable
groups. Nosocomial transmission affects both clients and health
workers [108], and has been associated with outbreaks such as
that seen in USA in the 1990s [109]. Working in health care
is a risk factor for latent TB, amplified by delays in diagnosis
and characterization [110–113]. In an endemic setting the tools
to detect latent infection and differentiate it from exposure are,
however, limited [113]. The annual risk of infection is 1.5% in the
general population [114], 1.7% in young doctors in Delhi [115],
and 4%–8% in nurses [110,112]. Recent media reports suggest
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Recommendations of the expert group, Focusing on Solutions for TB Control in Mumbai, 2012.
Active survey, notification and surveillance of MDR-TB cases.
Recognition of stigma and dealing with its elimination; guaranteeing client confidentiality.
Strengthening client counseling services.
Social support for clients.
Prevention of drop-out; increasing the role of civil society in preventing drop-out.
Increase in drug sensitivity testing and diagnostic laboratories.
Consistent and continuous supply of drugs.
Integration of the health system for TB and co-morbidities such as diabetes.
Implementation of existing RNTCP protocols related to client handling and infection control.
Preventing misuse of drugs by implementation of existing rules and regulations pertaining to over-the-counter sale.
Increased OR within the system. Facilitation of collaborative research projects to increase analytical capacity and introspection by the RNTCP.
Formation of a Technical Advisory Group, taking into consideration the available expertise in the city for surveillance and control measures.substantial numbers of infections over the last 3 years in staff at
Mumbai’s TB hospital, around half of infections leading to death.
Unfortunately, the view of TB as an occupational hazard may limit
efforts to prevent transmission.
For people visiting health posts for treatment, the risk of cross-
infection appears to be high. In a Mumbai study of previously
untreated clients with pulmonary TB, 32% of thosewho beganwith
a sensitive or mono-resistant profile had developed MDR-TB by
the fifth month. The fingerprint of 30% of paired isolates changed
between the first and fifth months, suggesting new infection that
might have been transmitted at health care facilities (unpublished
data).
4. Four suggestions for operations research
A recent meeting convened by the Foundation for Medical
Research brought together experts in an attempt to clarify the
agenda for action and research (Focusing on solutions for TB
control in Mumbai, February 2012). The broad recommendations
of the meeting are summarized in Table 2. To be honest, we find
the breadth of challenges and the existing prescriptions for OR
intimidating. It is part of the function of the Stop TBPartnership and
the RNTCP to take a broad view of TB control, and we add no local
value to the process if we do not contribute fairly clear opinions.
We therefore set ourselves the task of identifying four topics
for OR for TB control in Mumbai. We tried to think outside the
methodological comfort zone of knowledge, attitude and practice
studies, and studies of client and provider perceptions, toward
quantitative studies and more speculative modeling.
4.1. Better diagnosis, DST, classification and definition of cure
An example of the potential of existing records as modeling
material comes from a study from Andhra Pradesh [116]. The
RNTCP only conducts DST for clients judged to be at high risk
of MDR-TB. The study looked at the proportion of clients who
were judged to be ‘MDR suspects’, the proportion who ended up
with culture and DST, the proportion diagnosed with MDR-TB, and
the proportion who started appropriate treatment. Two percent
of 24 000 clients were judged as being at risk of MDR-TB and
55% of them had culture. There were substantial losses between
sputum collection, laboratory receipt, culture and DST results, and
subsequent treatment.
Modeling the effects of new technologies
We think that fairly simple modeling would be useful in pre-
dicting the effects of new approaches on population incidence and
prevalence. For example, there is justifiable current enthusiasm for
introducing Xpert MTB/RIF R⃝, which may be cost-effective for tu-
berculosis control in low-income countries [117,118]. Operations
research models that factor in the likely losses on the pathway
between symptom and cure would help us to identify pressurepoints in the systems that would need to surround the technology.
It would also be helpful to model the effects on transmission rates
of newer technologies for early diagnosis of TB in children.
Mapping and network modeling
Technologies such as geographic information systems (GIS),
combined with infectious disease modeling, are potentially useful
in identifying transmissionhotspots.Wewould like to see analytics
used in this way — along with DST — to answer questions about
acquisition of MDR-TB at health facilities and in communities [13].
Using active case detection to improve allocation of resources
The identification of MDR-TB in Mumbai is a passive exercise.
Countries have initiated active surveys for identifying TB in
areas with a high burden of drug resistance. Two approaches
to intensifying identification have been recently recommended
to the RNTCP. The first is compulsory notification of MDR-TB
(and, now, TB in general). The second is to carry out an active
survey in vulnerable populations such as informal settlements and
institutions. These approaches should link detected cases with
treatment and follow-up. Modeling would be useful in estimating
the projected reduction in transmission, and would allow realistic
planning for drug requirements and a more reliable computation
of costs.
Modeling the effects of changes in timing of activities
Current RNTCP guidelines recommendDST for patients who fail
any treatment regimen. Itwould beuseful to assess the appropriate
time for DST. Would it be effective, for example, to act on early
indicators of MDR-TB such as smear positivity in the second or
third months of treatment, in the absence of other risk factors?
How would providing DST results to clients on the same day
affect incidence and prevalence, given the potential reduction in
attrition? Andwhat would be the population effects of introducing
better tests at the end of treatment to confirm cure or predict
potential relapse?
4.2. Better prescribing practices across care providers
Modeling the effects of legislation and drug control
Irregular prescription practices by a variety of health care
providers are well described. We need to get the right drug combi-
nations, in the right regimens, to more clients [119,120]. One op-
tion for OR is to examine the reasons for suboptimal management,
particularly by private and informal sector providers, and particu-
larly the use of fixed-dose combinations whose curative efficacy is
uncertain. India is currently developing policies to regulate access
to anti-TB drugs, and it would be interesting tomodel the potential
effects of changes in availability across a range of scenarios. Sensi-
tivity analysesmight include increased use of the RNTCP, reduction
in treatment per se, and unauthorized prescription.
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inpatient management
TheWHO guidelines for treatment of MDR-TB recommend pre-
dominantly ambulatory care over hospitalization [120]. Benefits
have been demonstrated in one Mumbai study [78], but need to
be assessed in settings with different constellations of risk factors.
Models could include risks of non-adherence, relapse and default,
as well as risks of acquisition at facilities and in the community.
Modeling the effects of adverse drug reactions
Pharmacovigilance— including systematic surveillance of drug-
related problems — is needed because relatively little attention is
paid to the adverse reactions that can precipitate default [119].
Models describing the potential effects of this default on TB control
would help the RNTCP to counsel clients, improve adherence, and
retain public confidence.
4.3. Better integration of TB diagnosis and treatment with ART for HIV
Modeling diagnosis and transmissibility
The National Framework for Joint HIV/TB Collaborative Activi-
ties identifies priority areas for OR [121]. In addition to the RNTCP
and crossover recommendations on programmatic OR (Table 1), it
recommends the development of an algorithm to exclude active
TB in ART clients. Models that include a range of factors are intrin-
sic to the development of potential algorithms and to fine-tuning
their utility in terms of positive and negative predictive value. We
also need contact data in order to build epidemiologic models that
address the transmission of TB to people living with HIV, and from
them to uninfected individuals.
Modeling the effects of isoniazid preventive therapy
The National AIDS Control Organisation (NACO) acknowledges
the international evidence for a role for isoniazid preventive
therapy (IPT: giving isoniazid to ART clients to prevent the
development of TB). Although the national guidelines recommend
tests of the feasibility and cost-effectiveness of IPT, it has
not yet been adopted because of concerns about feasibility of
implementation and efficacy within India’s ART programme. A
rapid feasibility and efficacy study has been proposed by NACO
[122]. High levels of isoniazid resistance have been recorded [123],
and scenario modeling would help to clarify the population effects
of a potential programme at scale. IPT has also been suggested for
child contacts of TB patients [124], and with a current focus on the
diagnosis and prevention of childhood TB, evaluating the efficacy
of IPT in children would be useful.
4.4. Better infection control
Modeling the effects of changes to infrastructure and routines
DOTS Plus regimens for MDR-TB require both outpatient and
inpatient care and the resulting risk of transmission must be offset
by appropriate infection control measures. Particular issues are
the design of health posts and wards and the need for distinct
time-slots for different categories of clients given the integration
of TB carewith activities such asmaternity care and immunization.
Systems to fast-track smear positive individuals need to reflect
the caseloads at different facilities. Models could help us to
understand the transmission dynamics (especially of M/XDR-TB)
within facilities, and the likelihood of subsequent transmission in
the community [125].
5. Summary
The emergence of multi- and totally drug resistant TB in
Mumbai presents health workers and policy makers with anurgent, multifaceted problem. In identifying an agenda for
operations research to assist in tackling the challenges, we have
highlighted areas in which improved analysis of data and the
development of models focused on specific aspects of policy and
health service delivery could beneficially inform decisions on the
ground. We encourage operations researchers to engage with
academics, practitioners and policy makers working in global
health to respond to this agenda.
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